Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.4 HKD
−289.23 M HKD
2.10 B HKD
41.37 M
About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sector
Industry
CEO
Jun You Ge
Headquarters
Chengdu
Founded
2016
ISIN
CNE1000062J1
FIGI
BBG01H7W3K69
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. engages in the research and development, manufacture, and commercialization of novel drugs. It offers proprietary technology platforms focusing on the treatment of breast cancer, non-small cell lung cancer, gastrointestinal cancers, and colorectal cancer, as well as non-oncology diseases. The company was founded by Ge Xin Liu on November 22, 2016 and is headquartered in Chengdu, China.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 6990 is 514.0 HKD — it has increased by 2.59% in the past 24 hours. Watch Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stocks are traded under the ticker 6990.
6990 stock has risen by 4.31% compared to the previous week, the month change is a 19.86% rise, over the last year Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has showed a 211.52% increase.
We've gathered analysts' opinions on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H future price: according to them, 6990 price has a max estimate of 563.84 HKD and a min estimate of 354.27 HKD. Watch 6990 chart and read a more detailed Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock forecast: see what analysts think of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H and suggest that you do with its stocks.
6990 reached its all-time high on Aug 27, 2025 with the price of 498.2 HKD, and its all-time low was 60.6 HKD and was reached on Jul 11, 2023. View more price dynamics on 6990 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
6990 stock is 7.46% volatile and has beta coefficient of 0.64. Track Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock price on the chart and check out the list of the most volatile stocks — is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H there?
Today Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has the market capitalization of 113.33 B, it has decreased by −3.32% over the last week.
Yes, you can track Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H financials in yearly and quarterly reports right on TradingView.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H is going to release the next earnings report on Mar 30, 2026. Keep track of upcoming events with our Earnings Calendar.
6990 earnings for the last half-year are −0.70 HKD per share, whereas the estimation was −0.83 HKD, resulting in a 15.63% surprise. The estimated earnings for the next half-year are −1.26 HKD per share. See more details about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H earnings.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H revenue for the last half-year amounts to 1.04 B HKD, despite the estimated figure of 1.08 B HKD. In the next half-year revenue is expected to reach 1.01 B HKD.
6990 net income for the last half-year is −155.94 M HKD, while the previous report showed −625.93 M HKD of net income which accounts for 75.09% change. Track more Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H financial stats to get the full picture.
No, 6990 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 3, 2025, the company has 1.86 K employees. See our rating of the largest employees — is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H on this list?
Like other stocks, 6990 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock shows the buy signal. See more of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.